Orchestra BioMed (OBIO) CFO Reports 2,000‑Share Purchase

Rhea-AI Filing Summary

Orchestra BioMed Holdings, Inc. insider filing shows Chief Financial Officer Andrew Taylor reported a non-derivative purchase of 2,000 shares of the company on 08/25/2025 at a price of $2.55 per share. Following the transaction, the reporting person beneficially owned 482,788 shares. The Form 4 was filed by a single reporting person and bears the reporting person's signature dated 08/25/2025.

Positive

• Reported non‑derivative purchase of 2,000 shares on 08/25/2025 at $2.55 per share
• Filing discloses resulting beneficial ownership of 482,788 shares and is signed by the reporting person

Negative

• None.

Insights

Securities Analyst

TL;DR: CFO reported a small open-market purchase of 2,000 shares at $2.55, raising reported beneficial ownership to 482,788 shares.

The filing documents a straightforward, non‑derivative acquisition by the Chief Financial Officer on 08/25/2025. The disclosed purchase size is modest relative to total reported beneficial ownership, and no derivative transactions or dispositions are reported. The disclosure is routine for insiders and provides a clear, dated record of the transaction and post‑trade ownership.

Corporate Governance Expert

TL;DR: Routine Section 16 filing: officer purchase recorded with signature and standard disclosures.

The Form 4 includes required elements: reporter identity and address, officer title (Chief Financial Officer), transaction date, transaction code (P for purchase), number of shares acquired, acquisition price, and resulting beneficial ownership. There are no amendments, joint filings, or complex plan indicators noted. The filing meets routine compliance expectations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Taylor Andrew Lawrence

(Last) (First) (Middle)

C/O ORCHESTRA BIOMED HOLDINGS, INC.

150 UNION SQUARE DRIVE

(Street)

NEW HOPE PA 18938

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Orchestra BioMed Holdings, Inc. [ OBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	08/25/2025		P		2,000	A	$2.55	482,788	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Andrew Taylor	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did OBIO CFO report on the Form 4?

The CFO reported a non‑derivative purchase of 2,000 shares on 08/25/2025 at $2.55 per share.

How many Orchestra BioMed (OBIO) shares does the reporting person beneficially own after the transaction?

The reporting person beneficially owned 482,788 shares following the reported transaction.

Who filed the Form 4 for OBIO and what is their role?

The Form 4 was filed by Andrew Taylor, who is identified as the company's Chief Financial Officer.

When was the transaction executed and when was the Form 4 signed?

The transaction date is 08/25/2025 and the reporting person signed the form on 08/25/2025.

Did the Form 4 report any derivative transactions or dispositions?

No. The filing reports only a non‑derivative purchase and shows no derivative transactions or dispositions.